Is Qualigen Therapeutics Stock a Good Investment?
Qualigen Therapeutics Investment Advice | QLGN |
- Examine Qualigen Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Qualigen Therapeutics' leadership team and their track record. Good management can help Qualigen Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Qualigen Therapeutics' business and its evolving consumer preferences.
- Compare Qualigen Therapeutics' performance and market position to its competitors. Analyze how Qualigen Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Qualigen Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Qualigen Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Qualigen Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Qualigen Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Qualigen Therapeutics Stock
Researching Qualigen Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Qualigen Therapeutics recorded earning per share (EPS) of 3635.0. The entity last dividend was issued on the 26th of May 2020. The firm had 1:50 split on the 5th of November 2024.
To determine if Qualigen Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Qualigen Therapeutics' research are outlined below:
| Qualigen Therapeutics generated a negative expected return over the last 90 days | |
| Qualigen Therapeutics has high historical volatility and very poor performance | |
| Qualigen Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.2 M. Net Loss for the year was (12.48 M) with profit before overhead, payroll, taxes, and interest of 680.8 K. | |
| Qualigen Therapeutics currently holds about 6.62 M in cash with (10.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| Latest headline from gurufocus.com: Qualigen Therapeutics Announces Regained Compliance with Nasdaqs Minimum Bid Price Requirement ... |
Qualigen Therapeutics Quarterly Cost Of Revenue |
|
Qualigen Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Qualigen Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Qualigen Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of May 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Qualigen Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Qualigen Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-14 | 2023-06-30 | -0.52 | -0.68 | -0.16 | 30 | ||
2023-05-15 | 2023-03-31 | -1.3 | -1.0 | 0.3 | 23 | ||
2022-11-14 | 2022-09-30 | -1.3 | -1.0 | 0.3 | 23 | ||
2022-04-01 | 2022-03-31 | -1.7 | -2.0 | -0.3 | 17 | ||
2021-12-31 | 2021-12-31 | -1.7 | -2.0 | -0.3 | 17 | ||
2021-05-14 | 2021-03-31 | -1.6 | -1.3 | 0.3 | 18 | ||
2022-08-15 | 2022-06-30 | -1.6 | -1.1 | 0.5 | 31 | ||
2023-11-14 | 2023-09-30 | -0.92 | -0.08 | 0.84 | 91 |
Know Qualigen Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Qualigen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Qualigen Therapeutics backward and forwards among themselves. Qualigen Therapeutics' institutional investor refers to the entity that pools money to purchase Qualigen Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-06-30 | 252 | Bank Of America Corp | 2024-06-30 | 52.0 | Signaturefd, Llc | 2024-09-30 | 20.0 | Archer Investment Corporation | 2024-06-30 | 16.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-09-30 | 0.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 69.5 K | Geode Capital Management, Llc | 2024-06-30 | 30.2 K |
Qualigen Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.31 M.Market Cap |
|
Qualigen Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.60) | (6.27) | |
| Return On Capital Employed | 5.37 | 5.64 | |
| Return On Assets | (6.60) | (6.27) | |
| Return On Equity | 6.38 | 6.70 |
Determining Qualigen Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Qualigen Therapeutics is a good buy. For example, gross profit margin measures Qualigen Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Qualigen Therapeutics' profitability and make more informed investment decisions.
Evaluate Qualigen Therapeutics' management efficiency
Qualigen Therapeutics has return on total asset (ROA) of (0.7507) % which means that it has lost $0.7507 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.4166) %, meaning that it created substantial loss on money invested by shareholders. Qualigen Therapeutics' management efficiency ratios could be used to measure how well Qualigen Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Qualigen Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 12th of December 2024, Return On Equity is likely to grow to 6.70, though Return On Tangible Assets are likely to grow to (6.27). At this time, Qualigen Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 12th of December 2024, Other Current Assets is likely to grow to about 1.4 M, while Total Assets are likely to drop about 1.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.41) | (0.39) | |
| Tangible Book Value Per Share | (0.41) | (0.39) | |
| Enterprise Value Over EBITDA | (12.42) | (13.04) | |
| Price Book Value Ratio | (66.30) | (62.98) | |
| Enterprise Value Multiple | (12.42) | (13.04) | |
| Price Fair Value | (66.30) | (62.98) | |
| Enterprise Value | 218.7 M | 194.4 M |
At Qualigen Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.135 |
Basic technical analysis of Qualigen Stock
As of the 12th of December 2024, Qualigen Therapeutics holds the Variance of 44.64, risk adjusted performance of (0.06), and Coefficient Of Variation of (1,044). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Qualigen Therapeutics, as well as the relationship between them.Qualigen Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Qualigen Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Qualigen Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Qualigen Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Poirier over two weeks ago Acquisition by Michael Poirier of 29847 shares of Qualigen Therapeutics at 2.0663 subject to Rule 16b-3 | ||
Bensler Graydon over a month ago Insider Trading | ||
Shishir Sinha over a month ago Acquisition by Shishir Sinha of 100000 shares of Qualigen Therapeutics subject to Rule 16b-3 | ||
Braeden Lichti over two months ago Insider Trading | ||
Kruger Kurt H over two months ago Acquisition by Kruger Kurt H of 40000 shares of Qualigen Therapeutics subject to Rule 16b-3 | ||
Kruger Kurt H over three months ago Acquisition by Kruger Kurt H of 4000 shares of Qualigen Therapeutics at 2.935 subject to Rule 16b-3 | ||
Michael Poirier over six months ago Acquisition by Michael Poirier of 14437 shares of Qualigen Therapeutics at 2.5405 subject to Rule 16b-3 | ||
Ritter Andrew J over a year ago Qualigen Therapeutics exotic insider transaction detected |
Qualigen Therapeutics' Outstanding Corporate Bonds
Qualigen Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Qualigen Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Qualigen bonds can be classified according to their maturity, which is the date when Qualigen Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Qualigen Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Qualigen Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (1,044) | |||
| Standard Deviation | 6.68 | |||
| Variance | 44.64 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 47.03 | |||
| Value At Risk | (8.39) | |||
| Potential Upside | 9.21 | |||
| Skewness | (2.45) | |||
| Kurtosis | 14.22 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (1,044) | |||
| Standard Deviation | 6.68 | |||
| Variance | 44.64 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 47.03 | |||
| Value At Risk | (8.39) | |||
| Potential Upside | 9.21 | |||
| Skewness | (2.45) | |||
| Kurtosis | 14.22 |
Consider Qualigen Therapeutics' intraday indicators
Qualigen Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Qualigen Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Qualigen Therapeutics Corporate Filings
S1 | 9th of December 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
| 22nd of November 2024 Other Reports | ViewVerify | |
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Qualigen Stock media impact
Far too much social signal, news, headlines, and media speculation about Qualigen Therapeutics that are available to investors today. That information is available publicly through Qualigen media outlets and privately through word of mouth or via Qualigen internal channels. However, regardless of the origin, that massive amount of Qualigen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Qualigen Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Qualigen Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Qualigen Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Qualigen Therapeutics alpha.
Qualigen Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Qualigen Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Qualigen Therapeutics Corporate Management
| Christopher Lotz | VP Secretary | Profile | |
| MD MBA | Senior Officer | Profile | |
| Amy Broidrick | Chief Pres | Profile | |
| Wajdi AbdulAhad | VP Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.6 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Qualigen Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.